The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study by Clements, Alison et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Family Practice
Open Access Research article
The PSA testing dilemma: GPs' reports of consultations with 
asymptomatic men: a qualitative study
Alison Clements*1, Eila Watson1, Tanvi Rai1, Colleen Bukach1, Brian Shine2 
and Joan Austoker1
Address: 1Cancer Research UK Primary Care Education Research Group, Department of Primary Health Care, University of Oxford. Rosemary Rue 
Building, Old Road Campus, Headington, Oxford, OX3 7LF, UK and 2Department of Clinical Biochemistry, John Radcliffe Hospital, Headley Way, 
Headington, Oxford, OX3 9DU, UK
Email: Alison Clements* - alison.clements@dphpc.ox.ac.uk; Eila Watson - eila.watson@dphpc.ox.ac.uk; Tanvi Rai - tanvi.rai@dphpc.ox.ac.uk; 
Colleen Bukach - colleen.bukach@dphpc.ox.ac.uk; Brian Shine - brian.shine@orh.nhs.uk; Joan Austoker - joan.austoker@dphpc.ox.ac.uk
* Corresponding author    
Abstract
Background:  The National Health Service Prostate Cancer Risk Management Programme
(PCRMP) has recommended that screening for prostate cancer is available for asymptomatic men,
on the understanding that they have been provided with full and balanced information about the
advantages and limitations of the prostate-specific antigen (PSA) test. Guidance has been
distributed to all GPs in England and Wales to assist in the provision of information to men. This
study aimed to elicit GPs' accounts of their discussions with asymptomatic men who consult with
concerns about prostate cancer in order to identify the degree to which the PCRMP guidance was
reflected in these consultations.
Methods: Qualitative interview study. Semi-structured telephone interviews with 21 GPs from 18
GP practices in Oxfordshire.
Results: All GPs reported undertaking some discussion with asymptomatic men about the PSA
test. They described focussing most of the discussion on the false-positive and false-negative rates
of the test, and the risks associated with a prostate biopsy. They reported less discussion of the
potential for diagnosing indolent cancers, the dilemmas regarding treatment options for localised
prostate cancer and the potential benefits of testing. Considerable variation existed between GPs
in their accounts of the degree of detail given, and GP's presentation of information appeared to
be affected by their personal views of the PSA test.
Conclusion: The GPs in this study appear to recognise the importance of discussions regarding
PSA testing; however, a full and balanced picture of the associated advantages and limitations does
not seem to be consistently conveyed. Factors specific to PSA testing which appeared to have an
impact on the GPs' discussions were the GP's personal opinions of the PSA test, and the need to
counter men's primarily positive views of the benefits of PSA testing. Awareness of the impact of
their views on the consultations may help GPs give men a more balanced presentation of the
benefits and limitations of the PSA test.
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Background
Screening for prostate cancer is controversial. The high
incidence and mortality rates [1], and the fact that local-
ised disease can potentially be treated, has led to wide-
spread calls for prostate cancer screening. However, there
is ongoing debate as to whether screening would result in
more harm than good [2,3]. There is no strong evidence
that screening would result in reduced mortality from the
disease [4,5]. The PSA test has relatively high false positive
and false negative rates, prostate biopsies can miss can-
cers, and the highly variable nature of prostate cancer
means there is potential for diagnosis of indolent cancers
that may never present as a problem [6,7].
In the UK, the National Screening Committee has recom-
mended that a prostate cancer screening programme
should not be introduced [8]. However, in response to
growing public concern about the disease, in 2001 the
Department of Health introduced the Prostate Cancer
Risk Management Programme (PCRMP). Central to this
programme is the recommendation that any man who
wishes to have a PSA test should have access to the test, pro-
vided he has been given full information regarding the possible
benefits and limitations associated with receiving a test [9]. A
national information pack was developed to provide
guidance for primary care in providing men, who ask their
GPs about testing for prostate cancer, with clear and bal-
anced information on the benefits and limitations of test-
ing [10]. The key information points are summarised in
Table 1.
It is not known to what extent primary care consultations
about PSA testing reflect the guidance provided by the
PCRMP. Our study sought to understand GPs' interac-
tions with men who consult them without having any of
the symptoms associated with the disease (asymptomatic
men) and to identify the degree to which the PCRMP
guidance was reflected in the consultations. This paper
describes the discussions that GP's report having with
these men, as well as factors that appear to influence the
nature and content of the discussions. The discussion con-
siders the extent to which it may be possible for GPs to fol-
low the PCRMP guidance within the consultation.
Methods
Recruitment
A purposive sample of GPs was identified through first
PSA test requests made for patients, of any age, to the
Department of Clinical Biochemistry, John Radcliffe Hos-
pital, Oxford. As part of a separate study, questionnaires
had been sent to the requesting GPs. Of the 173 GPs who
returned a questionnaire, 94 indicated that they would be
willing to also take part in a telephone interview. Consec-
utive GPs were invited to take part in this study. 21 GPs,
from 18 surgeries, were interviewed within the time frame
of the study. GPs were paid £50 as reimbursement for the
time spent. See Table 2 for the characteristics of recruited
GPs.
Data collection
Semi-structured telephone interviews were conducted by
TR and EW. An interview guide was used to elicit i) the
content of discussions GPs have with asymptomatic men
who consult with concerns about prostate cancer/PSA
testing and ii) the attitudes of GPs toward the PSA test.
Other areas were covered but are not the topic of this
paper. With permission the interviews were tape-recorded
and fully transcribed.
Analysis
Data analysis was undertaken by AC, TR & EW using the
framework approach [11]. Through reading and re-read-
ing the data, an analytic framework was developed from
the identification of the key issues within the data (using
a priori issues and questions from the aims of the study,
in addition to issues raised by the participants). This cod-
ing framework was used to analyse all data, with themes
added as new issues were identified in subsequent stages
of the analysis. A transparent coding scheme, together
with regular discussions between the researchers during
the coding and interpretation stages helped to ensure the
credibility and trustworthiness of the findings [12]. Data
across the whole set as well as within each individual
interview were examined. The software package, Atlas.ti,
was used to assist in the management of the data.
Results
All GPs in the study reported having some degree of dis-
cussion about PSA testing with asymptomatic men who
consulted with concerns about prostate cancer. However,
we found considerable variation within the reported dis-
cussions, with a tendency for greater emphasis to be
placed on certain key points and disparity in the degree of
detail given. We also identified differences in the imparti-
ality with which GPs appeared to present the information.
Content of GPs' discussions with men
False-positive and false-negative results
The GPs in our study described feeling that it was impor-
tant for men to understand the imprecise nature of the
PSA test, and, without exception, they reported having
discussed the possibility of the PSA test yielding false-pos-
itive and false-negative results.
"I normally tell them that men with prostate cancer
usually have high levels of PSA and men without pros-
tate cancer usually have low levels but there are some
men who have higher than normal levels who don't
have prostate cancer and some men who've got quiteBMC Family Practice 2007, 8:35 http://www.biomedcentral.com/1471-2296/8/35
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low levels who turn out that they do have prostate can-
cer..." ID19
The biopsy stage
Many GPs said they would explain that the PSA test alone
is not sufficient to diagnose prostate cancer and a prostate
biopsy is the probable next stage following a raised PSA
result.
"...it's usually part of my talk that ... if it is positive then
the only way we go further and know for sure would
be a biopsy..." ID10
However, the uncertainty of what to do if the PSA result is
only slightly raised, is also often discussed.
"...[I talked] about the false-positives and negatives,
and the problem of marginally raised results, what to
do with it. The difficulties in deciding what to do with
a slightly raised PSA ....." ID3
GPs frequently reported discussing the potential pain and
discomfort of a biopsy. Less often they described men-
tioning that some biopsies are unwarranted due to false-
positive PSA results, and that false reassurance can result
from false-negative biopsy results.
"...[I say that] it's not a very good test and it's, there's a
fair chance that it'll show up positive and you won't
have any prostate cancer ... so that can land you in all
sorts of unpleasant biopsies and things for nothing."
ID17
While many GPs reported that they would discuss issues
related to a prostate biopsy, there was considerable varia-
tion in the degree of detail that they said they give. Some
would provide minimal information.
"...do you actually mention the possibility of having to have
a biopsy if the PSA is raised ...? I'm not sure I get as far,
I would say "If it's raised and it's raised enough that we
need to refer you for more investigations," and I think
that would be as far I would get..."ID2
Others report giving much more expansive descriptions.
"... then I go on a bit to talk about biopsies... that when
they do an ultrasound test they can sometimes see an
area of abnormality in which case they can biopsy that
area..... but if they can't see any areas of abnormality
then they take six or eight blind biopsies and the
results of those biopsies can be again normal or abnor-
mal. And when they're normal then that's usually reas-
suring but of course if you're taking blind biopsies you
Table 1: Key points identified by the PCRMP for men to be aware of prior to undertaking a PSA test
• the PSA test facilitates the early detection of prostate cancer at a stage when potentially curative treatments can be offered
• there is currently no strong evidence that PSA testing reduces mortality from prostate cancer
• not all men with raised PSA will have prostate cancer/the PSA test will not detect all prostate cancers
• prostate cancer is diagnosed through a prostate biopsy which can be uncomfortable or painful
• prostate biopsies will not detect all prostate cancers
• prostate cancers range from aggressive to slow growing forms – slow growing tumours may not result in symptoms or shorten life expectancy
• there is no evidence about the optimum treatment for localised prostate cancer
• some treatments for prostate cancer can have significant side effects
Table 2: Characteristics of recruited GPs
n%
Gender
Male 15 71.4
Female 6 28.6
Time practising (years)
<5 3 14.3
5–15 6 28.6
16–25 7 33.3
>25 5 23.8
Age (years)
30–39 6 28.6
40–49 6 28.6BMC Family Practice 2007, 8:35 http://www.biomedcentral.com/1471-2296/8/35
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may have missed the area of abnormality......and so it
can never be absolutely foolproof ..." ID18
Potential for diagnosis of indolent cancers
While less frequently discussed than the previous key
points, a number of GPs said they would discuss the vari-
able nature of prostate cancer, with an emphasis on the
possibility of identifying indolent cancers which may
never cause a problem.
"... my usual line is, when old boys die an awful lot of
them have been found to have prostate cancer that
they had no idea was there and has never caused a jot
of problems...and I try and explain that to them 'You
may turn out to have the prostate cancer that is just
going to sit there for thirty years and do nothing...' "
ID15
GPs who said that they either would not include a discus-
sion of the range and nature of prostate cancers, or would
do so in a very limited way, gave several reasons for this.
Some felt that this information is often not relevant to
men at this stage of the process.
"I feel I'm in second line for that (discussion of range of
prostate cancers) because if they go ahead and have the
biopsy, say they have the PSA test and it's positive then
you have to, you are obliged to refer ... the urologists
are obliged then to investigate further.....so it's very
much their stance isn't it?" ID8
Some GPs believe this information is less relevant for
younger men, as having prostate cancer at an early age is
more likely to have serious implications.
"I think it's useful in the elderly...but I don't think it's
useful in someone aged 50...because they, if they did
get diagnosed with prostate cancer at 50 then they
probably would die of it..." ID16
Treatments for prostate cancer
Very few GPs in the study reported discussing treatment
options for early prostate cancer. Those who did said they
would tend to emphasise the potential side effects and
lack of consensus about which treatments, if any at all,
may be effective.
"I think people need to realise ...even if it is diagnosed,
as far as I know there is still uncertainty as to what the
best treatment is even so if you know you've got it, it's
hard to know what to do about it" ID19
Again, relevance of the information to men at this stage of
the process was cited as a reason for omitting treatment
option discussions.
"you only have a limited consultation ...you don't
want to frighten people if they haven't got it, like you
don't say to every woman before they go for a mam-
mogram all the pros and cons of chemotherapy and
radiotherapy for breast cancer do you?" ID7
GPs reported very little corresponding discussion about
how treatment could be potentially beneficial.
"... I don't go into all the detail about what the various
treatment options are... just to say that there are effec-
tive treatments particularly if it's caught early which is
the rationale really for screening for it". ID14
Several factors which had an impact on what was dis-
cussed within the consultations are specific to the PSA test
and have been considered in the relevant sections above;
others factors relate to primary care consultations in gen-
eral.
Written information
The amount of detail discussed was affected by the use of
written information. Some GPs found patient informa-
tion leaflets a useful supplement to, or in some cases, a
replacement for detailed discussion.
-"...so you tend to give the leaflet out? Oh always. Do you
think that is the best way to provide patient information, for
GPs? Um well I think the evidence is that people don't
remember what you say to them ... and it also means
that you know wives and families generally have a
chance to share it, so I know I'm also, everything that
can be given in leaflet form should be really" ID13
Time factors
Explaining and ensuring an understanding of the key
points was felt by many GPs to be a time consuming proc-
ess. Some felt that a ten minute consultation, focussing
only on the PSA test, may give sufficient time to convey
the main points, though this would not be so if more than
one concern is brought to a consultation and the issue of
PSA testing raised at a late stage. Other GPs felt that even
a full 10 minute consultation would not be sufficient.
"I don't know if our language has developed enough with
patients nor their, nor their thoughts. I think, I think
they're difficult concepts.....So I think, I think getting a
patient to, to a position of truly informed decision-making
is, is difficult and it is very time consuming and maybe
that's the problem, maybe I just feel we haven't got the time
to spend with every patient doing that" ID5BMC Family Practice 2007, 8:35 http://www.biomedcentral.com/1471-2296/8/35
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Degree of balance in discussion
GPs' opinions about the PSA test
We found differences in the way GPs described how they
present information to men, which in part seems to reflect
the wide range of opinions held about the usefulness of
the PSA test as a screening tool. Some GPs who expressed
strong views against the value of the PSA test, quite clearly
portray this view to men in their discussions, either
directly:
" ...I think I would really give very directive counsel-
ling and try and talk them out of it and say "It's a waste
of time and really I advise against it." ID17
or indirectly, by highlighting the drawbacks:
"... I do tend to talk about the impossible situation you
get yourself into if you have a PSA that's raised. You're
going to then not know whether to have prostate biop-
sies and so on... and all the risks of that... so that's how
I tend to try to put them off..... by saying 'The chances
are it will come back in some unhelpful grey area and
you won't know what to do...' " ID13
GPs who have either neutral, or more positive views about
the usefulness of PSA screening tend to present men with
information on the benefits and limitations of testing,
with the intent of allowing the men to reach their own
decisions. One such GP, who provided very full informa-
tion on testing, did note that most men he counselled
went on to be tested.
"I'm probably a bit pro-testing ... I don't positively dis-
suade them as it were, I give them all the information
and they usually go on to have a test, I would say ...".
ID18
Men's prior opinions of PSA testing
Men's predominantly positive attitudes towards PSA test-
ing, often due to press coverage or personal recommenda-
tion, also often had an effect on the way GP's presented
the information. GPs described emphasising the draw-
backs of testing, thus presenting somewhat biased infor-
mation to counter the faith men appeared to place in the
test.
"...and people in general are quite keen to have, men
in general are quite keen to have a prostate blood
test.....unfortunately... [laughs]... I certainly sound neg-
ative about it to counteract the over-positive things
that they've read ..." ID4
Impact of balance on GP's behaviour
While personal views about PSA testing seem to be an
important factor in determining how impartial GPs are in
presenting information, and many GPs did say they
would attempt to dissuade men from being tested, only
one GP in our study said he would deny a man's request,
and that related specifically to men under the age of 50.
Concerns about being held responsible for missing a can-
cer affected the tendency for some GPs to dissuade a man
from undergoing a PSA test. The following GP said he
would highlight the negative elements of testing to men,
but would carry out a test if they persisted in their request.
"...people have read about it (PSA test) and are con-
vinced it's the bees knees ...and if you don't do it and
it turns out that subsequently you could have detected
prostate cancer I think you know you, you're going to
be on a sticky wicket..." ID15
Discussion
Summary of findings
While GPs' descriptions of their consultations suggest that
they recognise the importance of discussions with asymp-
tomatic men about the PSA test, a full and balanced pic-
ture of the associated benefits and limitations does not
appear to be consistently conveyed. GPs reported talking
about some of the limitations of the PSA test: the false-
negative and false-positive results and the potentially
unpleasant nature of a prostate biopsy, while much less so
about the potential for identification of indolent cancers
and the lack of evidence regarding treatment effectiveness.
Relatively little attention seems to be given to the poten-
tial benefit of PSA testing: the identification of early pros-
tate cancer which could be successfully treated. However,
there was considerable diversity in the degree of detail GPs
reported conveying to men about these points. The GPs'
personal opinions of the PSA test, and their perceived
need to counter men's primarily positive views of the ben-
efits of PSA testing appeared to have an impact on the GPs'
discussions.
We have identified both practical and ideological barriers
faced by GPs in providing a full and balanced picture of
the benefits and limitations of the PSA test. Constraints
such as consultation time, could be addressed by the con-
sistent provision of written information, together with a
second consultation prior to testing. More complex to
address may be the impact of GPs' views on the usefulness
of the PSA test and their feelings of the relevance of spe-
cific information at particular times.
Providing information to patients about clinical issues for
which there is no established evidence base can be prob-
lematic, and it is understandable that GPs' discussions
could reflect their clinical experience and personal opin-
ion. The views held by many GPs about the value, or lack
of value of the PSA test appear to be a driving force behind
the information they give and how it is presented. SupportBMC Family Practice 2007, 8:35 http://www.biomedcentral.com/1471-2296/8/35
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for this finding comes from work in the US. Cooper has
shown that views held, both for and against PSA testing,
influence guideline adherence. Physicians holding posi-
tive views tended to screen routinely with little accompa-
nying discussion, while those influenced by the lack of
evidence of benefit, and their personal and professional
experiences of the limitations of the PSA test were more
likely to discuss the implications of testing [13]. Work by
Chan also suggested a belief that the benefits of testing
outweigh the risks may create a bias in the discussion of
PSA testing with patients [14]. It may be that the views of
GPs regarding the value of the PSA test will be affected by
evidence from two large-scale randomised screening trials
being conducted in Europe and the USA, aiming to assess
whether PSA screening reduces prostate cancer mortality
[15]. Trial results are expected in 2008 and should enable
definitive recommendations about the value of PSA
screening to be made. This will change the position GPs
are currently in, of being expected to provide information
without good evidence of the impact of PSA testing on
mortality. However, while a national screening pro-
gramme may follow if the trials do provide evidence of
mortality reduction, the development and implementa-
tion of such a programme is likely to take several years. In
the meantime, information about the benefits and limita-
tions of testing will still need to be portrayed to men, and
it is important that how GPs interpret and incorporate
new findings into their consultations continue to be
understood.
Our findings indicate that a GP's perception of the rele-
vance of having certain information while deciding
whether to undergo a test may also have an impact on the
balance of the discussions. It is interesting that GPs
reported being less likely to discuss the potential for diag-
nosing indolent cancers and the lack of evidence for the
effectiveness of prostate cancer treatments, as these two
points are often cited as reasons against introducing pop-
ulation screening [16,17]. On the other hand, it has been
proposed that it may be misleading to focus on the poten-
tial for over-diagnosis when discussing screening with
younger men [18]. Other factors, such as the complexity
of conveying concepts of risk, responding to personal
knowledge of their individual patients and an awareness
that not all men want information may also be important
determinants in shaping the discussion.
The lack of balance that some GPs report in their discus-
sions can also be understood in terms of what they see as
men's over-positive views of the PSA test. This is not an
issue peculiar to prostate cancer screening; as with many
screening tests, the primary benefit to the patient is detec-
tion of curable disease, which to an individual, may out-
weigh the greater number of potential drawbacks. The
apparent concentration on the test's limitations may be an
attempt by GPs to counter and bring a sense of balance to
the men's views. However, the impact of this may be that
the potential benefits of PSA testing are not discussed, but
left implicit, possibly creating an imbalance in the oppo-
site direction.
It may help GPs to be conscious of the impact that their
views of the PSA test and their perceptions of men's need
for information may have on their consultations. Incorpo-
ration of our findings in a revision of the PCRMP informa-
tion pack will hopefully enable GPs to present
information on PSA testing to men in a consistently bal-
anced way.
Strengths and limitations
This study is the first to address the discussions about PSA
testing that take place during GP consultations with
asymptomatic men concerned about prostate cancer, and
as such provides a valuable insight into the extent to
which the implications of undergoing a PSA test are dis-
cussed. The value of qualitative research lies in the depth
of understanding gained from detailed descriptions of
specific experiences. For this reason the number of partic-
ipants in a qualitative study is necessarily small. However,
we do acknowledge that the relatively small number of
GPs interviewed from those available may mean there
were a range of experiences that we have not captured.
Interviews reliant on recollections of an event can suffer
from recall bias. While audio-taped consultations would
have provided an accurate record of the actual consulta-
tion, the infrequency of relevant consultations and the
complexity of determining in advance that the topic
would be discussed and obtaining consent made this
approach unfeasible. A further limitation is that GPs for
this study were recruited from one regional area. How-
ever, given the wide range of behaviours and views
described, and that very few GPs' accounts reflected a
'model' consultation according to the guidance offered,
there is nothing to strongly suggest that our data collec-
tion methods or recruitment strategy have limited our
findings.
Implications for future research
Extending this initial work through the use of observation
methods may add to our understanding of consultations,
though the methodological difficulties inherent in such a
study should not be underestimated. Furthermore, while
the GPs in our study indicated they would not deny a man
over 50 a PSA test, we do not know how men are affected
by the discussions they have with their GP. It is important
to understand men's perception of the information they
are given, whether they want it and what use of it they
make. We have completed an interview study looking at
consultations prior to PSA testing from men's perspective,
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Conclusion
The GPs in this study appear to recognise the importance
of discussions regarding PSA testing; however, a full and
balanced picture of the associated advantages and limita-
tions does not seem to be consistently conveyed. Factors
specific to PSA testing which appeared to have an impact
on the GPs' discussions were the GP's personal opinions
of the PSA test, and the need to counter men's primarily
positive views of the benefits of PSA testing. Awareness of
the impact of their views on the consultations may help
GPs give men a more balanced presentation of the bene-
fits and limitations of the PSA test.
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